FGF13

Across TCGA pan-cancer cohorts, FGF13 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of FGF13’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where FGF13 RNA is repressed in tumor relative to normal tissue. In most cancer types FGF13 is over-expressed in tumor, although a few such as BLCA and THCA show the opposite, repressed pattern.

BLCA, THCA, and LIHC are the cancer types where FGF13 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FGF13 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	IV	−0.855	<.001	11	view →
THCA	Male	II,III,IV	−0.973	<.001	9	view →
LIHC	Male	II,III,IV	+1.162	<.001	8	view →
KIRC	All	III,IV	−0.308	.010	7	view →
COAD	All	II,III,IV	−0.348	.002	6	view →
BRCA	Female	II,III,IV	−0.342	<.001	6	view →
CHOL	Female	All	+2.200	<.001	5	view →
LUAD	Male	All	+0.618	<.001	5	view →
READ	All	III,IV	−0.605	<.001	4	view →
PAAD	Female	All	−0.545	.021	4	view →
ESCA	Female	All	−0.996	<.001	2	view →
UCEC	All	All	−0.659	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

FGF13–BLCA

Open the BLCA breakdown →